Dr. Reddy’s v. Genentech & AbbVie: Federal Circuit Dismisses Anti-CD20/BCL-2 Appeals
Dr. Reddy’s Laboratories brought an infringement appeal against Genentech, Hoffmann-La Roche, and AbbVie over US10993942B2, a patent covering combination therapy using a type II anti-CD20 antibody with a selective BCL-2 inhibitor. The Federal Circuit granted motions to dismiss both appeals, with each side bearing its own costs, closing the case after 472 days.
Federal Circuit ends anti-CD20/BCL-2 dispute without merits review
Filed on 16 October 2023, case 24-1048 pitted Dr. Reddy’s Laboratories, Ltd. against Genentech, Inc., Hoffmann-La Roche, Inc., and AbbVie, Inc. at the United States Court of Appeals for the Federal Circuit. The underlying dispute centred on US10993942B2, a patent protecting a combination therapy approach pairing a type II anti-CD20 antibody with a selective BCL-2 inhibitor — a regimen with significant relevance to hematologic oncology treatment protocols.
The Federal Circuit granted motions to dismiss both appeals on 30 January 2025, closing the case after 472 days without issuing any ruling on the merits of the infringement claims. The dismissal order specifies that each side shall bear its own costs, suggesting a negotiated or procedural resolution rather than a contested merits adjudication. No substantive finding on patent validity or infringement was rendered at the appellate level.
The absence of a merits ruling leaves the underlying legal questions — including the scope and enforceability of US10993942B2 — unresolved through this proceeding. The symmetric cost allocation is consistent with a settlement or agreed withdrawal of claims, though the public record does not confirm this. IP practitioners should note that the patent remains active in the landscape, and the dismissal does not create binding precedent on the combination therapy claims at issue.
Filing to Appeal Dismissed in 472 days
472 days — slightly above typical Federal Circuit appeal resolution timelines
Appeal dismissed: what the Federal Circuit’s ruling means for both parties
Dismissal on motion — no merits adjudication at appellate level
The Federal Circuit granted motions to dismiss the appeals, meaning the court did not evaluate the underlying infringement claims or patent validity on their merits. A motion-based dismissal at the appellate level typically reflects a procedural deficiency, mootness, lack of standing, or — consistent with the symmetric cost order — a resolution between the parties that rendered the appeal unnecessary.
Procedural dismissalDr. Reddy’s exits without a favourable merits ruling
As the party that brought the appeal, Dr. Reddy’s Laboratories obtains no appellate vindication of its infringement position. The dismissal does not establish that the patent was infringed. However, the absence of a merits ruling also means no adverse precedent was created against Dr. Reddy’s claims. The symmetric cost allocation suggests neither party extracted a punitive outcome from the other.
No merits win for appellantGenentech, Roche & AbbVie avoid appellate infringement finding
The dismissal spares Genentech, Hoffmann-La Roche, and AbbVie from any appellate determination of infringement liability on US10993942B2. The patent’s enforceability against their combination therapy products is not adjudicated through this proceeding. While this is a procedural win, the underlying patent remains in force and could theoretically support future enforcement actions through separate proceedings.
No infringement ruling issuedBCL-2/anti-CD20 patent landscape remains unsettled post-dismissal
With no merits ruling on US10993942B2, the scope and enforceability of combination therapy claims in the anti-CD20/BCL-2 space remain legally ambiguous through this case. Competitors developing or marketing similar hematologic oncology regimens should treat this patent as an active risk. The dismissal creates no safe harbour. FTO analysis against US10993942B2 remains advisable for any entrant in this therapeutic class.
Patent risk unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Dr. Reddy’s Laboratories, Ltd. | Company | Indian pharmaceutical company — holder of US10993942B2 covering anti-CD20/BCL-2 combination therapySearch in Eureka ↗ |
| Defendant | Genentech, Inc. | Company | Genentech, Hoffmann-La Roche, and AbbVie — major biopharmaceutical companies in oncology therapeuticsSearch in Eureka ↗ |
| Co-Defendant | Hoffmann-La Roche, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | AbbVie, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brandon Michael White | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Perkins Coie LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for Genentech, Inc.Search in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing Genentech, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘The motions are granted. The appeals are dismissed. Each side shall bear its own costs.’ — is a purely procedural disposition. No claim construction, validity determination, or infringement finding was made. The plural ‘appeals’ confirms multiple appellate tracks were terminated simultaneously. The cost neutrality provision, while standard in some dismissals, is notable here given the multi-defendant structure and suggests the resolution may have been consensual rather than driven by a procedural defect alone.
US10993942B2 — Anti-CD20 and BCL-2 Inhibitor Combination Therapy
US10993942B2 (application number US16/827650) protects a combination therapy regimen pairing a type II anti-CD20 antibody — such as obinutuzumab — with a selective BCL-2 inhibitor. BCL-2 inhibitors block anti-apoptotic proteins that allow cancer cells to evade programmed cell death, while type II anti-CD20 antibodies target B-cell surface markers, together creating a synergistic mechanism particularly relevant to B-cell malignancies including CLL and NHL. The patent’s claims encompass this therapeutic combination as a distinct IP-protected approach to hematologic oncology treatment.
The strategic importance of US10993942B2 lies in its position at the intersection of two commercially significant biologics classes. With venetoclax (AbbVie/Genentech) established as the leading BCL-2 inhibitor and obinutuzumab (Genentech/Roche) prominent in anti-CD20 therapy, the patent’s combination claims could implicate a multi-billion dollar treatment market. For biosimilar developers and generic entrants considering either therapeutic class, understanding the claim scope of this patent is critical to any market entry strategy in hematologic oncology.
Should you run an FTO analysis against US10993942B2?
Any company developing, commercialising, or planning to launch a product that combines a type II anti-CD20 antibody with a selective BCL-2 inhibitor — including biosimilars of obinutuzumab or venetoclax used in combination protocols — should treat US10993942B2 as an active clearance risk. The Federal Circuit dismissal in this case provides no legal safe harbour and creates no invalidity precedent. The patent remains in force and its claim scope was never adjudicated in this proceeding.
PatSnap Eureka’s FTO Search Agent enables R&D and regulatory teams to map the specific claim language of US10993942B2 against product formulations, dosing regimens, and combination protocols under development. Eureka surfaces prosecution history, related family members, and forward citations that may reveal design-around opportunities or additional blocking IP in the BCL-2 and anti-CD20 landscape — helping teams make informed go/no-go decisions before clinical or commercial investment.
Run a freedom-to-operate analysis on US10993942B2 to assess your product’s exposure
Run FTO in Eureka →Related Federal Circuit cases: anti-CD20 and BCL-2 inhibitor patent disputes
Explore Federal Circuit appeals involving anti-CD20 antibody and BCL-2 inhibitor patents, including comparable dismissals and infringement actions in hematologic oncology.
What this case signals for the oncology combination therapy IP landscape
A Federal Circuit dismissal without merits review keeps US10993942B2 in active contention — the BCL-2/anti-CD20 space remains exposed to future enforcement.
Symmetric cost orders often signal pre-dismissal settlement activity
When a Federal Circuit appeal is dismissed and each side bears its own costs, this pattern is consistent with a negotiated resolution reached after the appeal was filed. It suggests the commercial dispute was resolved privately, even if the settlement terms remain confidential. Practitioners should monitor licensing activity involving US10993942B2 as a follow-on indicator.
The patent survives — no invalidity or non-infringement ruling was issued
US10993942B2 remains fully enforceable. The dismissal creates no estoppel, no invalidity finding, and no claim construction precedent. Any party operating in the type II anti-CD20 plus selective BCL-2 inhibitor space — including biosimilar developers — should conduct independent FTO analysis rather than relying on this dismissal as a clearance signal.
Dr. v Genentech — key questions answered
The Federal Circuit dismissed both appeals in case 24-1048 on 30 January 2025, granting motions to dismiss without issuing any merits ruling on infringement or validity of US10993942B2. Each side was ordered to bear its own costs. The underlying patent, covering combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor, remains in force.
US10993942B2 protects a combination therapy regimen using a type II anti-CD20 antibody alongside a selective BCL-2 inhibitor, targeting B-cell malignancies such as CLL and NHL. This combination encompasses treatments involving obinutuzumab and venetoclax — products associated with Genentech, Hoffmann-La Roche, and AbbVie — making the patent’s claim scope commercially significant across the hematologic oncology market.
No. The dismissal was procedural and no merits determination was made. The Federal Circuit did not rule on validity or infringement. US10993942B2 remains a fully enforceable patent. Parties operating in the anti-CD20 or BCL-2 inhibitor combination therapy space cannot rely on this dismissal as a clearance signal and should conduct independent FTO analysis.
The inclusion of Hoffmann-La Roche alongside Genentech reflects their affiliated corporate relationship in the biologics space. AbbVie’s presence as a co-defendant is consistent with its commercial interest in venetoclax (Venclexta), a selective BCL-2 inhibitor frequently used in combination regimens. The multi-defendant structure suggests the patent claims were construed broadly enough to implicate multiple commercial stakeholders.
A symmetric cost order — where neither party recovers costs from the other — is sometimes standard in procedural dismissals but is notably consistent with a consensual resolution. In contested Federal Circuit appeals, prevailing parties may seek costs. The mutual cost allocation here suggests the dismissal may have followed a negotiated agreement between Dr. Reddy’s and the defendants, though the public record does not confirm settlement terms.
PatSnap Eureka searches patents and litigation data to answer instantly.